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INTRODUCTION
The nm23 gene was first classified as a metastasis suppres-
sor gene on the basis of its reduced expression in several meta-
static melanoma cell lines relative to nonmetastatic counter-
parts (1). Subsequently, the low expression of nm23-H1 pro-
tein has been described as being linked to an increased meta-
static potential in breast carcinoma, hepatoma, and gastric
carcinoma, implying its role at inhibiting metastasis in a vari-
ety of human cancers (2-4). In other tumors, such as neurob-
lastoma, pancreatic carcinoma, and head and neck carcinomas,
surprisingly, the opposite trend has been reported (5-7). 
Malignant lymphomas constitute a heterogenous group of
disorders, comprising different histogenesis and variable clini-
cal outcomes. The histologic types and clinical staging are
well known as prognostic indicators. Nevertheless they can-
not accurately predict a clinical outcome in an individual case.
Thus, a continuous necessity for reproducible quantitative
methods has been required to confer additional prognostic
information and to guide the clinician in the selection of the
most appropriate therapeutic approach.
The previous studies of nm23-H1 expression in malignant
lymphomas revealed that overall survival rates were signifi-
cantly lower in the patients with nm23-H1-positive lym-
phomas than in those with nm23-H1-negative lymphomas
(8-12). There has been only one study describing no muta-
tional change of nm23-H1 gene in malignant lymphomas
(13). The aims of this study are to determine the significance
of nm23-H1 protein expression as a prognostic indicator and
to detect the frequency of nm23-H1 gene mutation in non-
Hodgkin’s lymphomas.
MATERIALS AND METHODS
Materials
One hundred fifty non-Hodgkin’s lymphomas were select-
ed from the pathology file in the Department of Pathology,
Anam and Guro Hospitals of Korea University, Korea. The
tissues were routinely processed with 10% buffered formalin
fixation and paraffin embedding. The diagnosis and classifi-
cation of lymphomas were dependent upon the routine histo-
logic sections and immunohistochemical staining. They were
supplemented by TCR rearrangement study and followed
by the WHO classification (14). The studied cases were 106 B
cell lymphomas (85 diffuse large B cell lymphomas [DLBCL],
18 marginal zone B cell lymphomas [MZL], and 3 mantle
cell lymphomas [MCL]), and 44 T cell lymphomas (25 periph-
eral T cell lymphoma, not otherwise specified [TCLNOS],
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nm23-H1 Protein Expression and Gene Mutation in 150 Patients with
Non-Hodgkin’ s Lymphomas
The metastasis-suppressing role of the nm23 gene in the metastatic spread of malig-
nant tumor is still debated. We examined the nm23-H1 protein expression and gene
mutation in non-Hodgkin’s lymphomas to compare with the clinicopathologic para-
meters. The expression of nm23-H1 protein was immunohistochemically examined
in 150 cases of non-Hodgkin’s lymphomas; 85 diffuse large B cell lymphomas (DL-
BCL), 18 marginal zone B cell lymphomas (MZL), 3 mantle cell lymphomas, 25 peri-
pheral T cell lymphomas, not otherwise specified (TCLNOS), and 19 NK/T cell lym-
phomas (NK/T). Eighty-one cases (58 DLBCL, 6 MZL, 4 TCLNOS, and 13 NK/T)
were studied for nm23-H1 gene mutation in exon 1 to 5. The high expression of
nm23-H1 protein was associated with the high IPI score (p=0.019) and the low sur-
vival rate of the patients (p=0.0039). The gene mutation of nm23-H1 was detected
in 10.3% of DLBCL and 30.7% of NK/T; but none in MZL and TCLNOS. The muta-
tion was found in exon 1 in 5 cases, exon 2 in two cases, exon 4 in one case and
both exon 1 and 2 in two cases. Our results suggest that the expression of nm23-
H1 protein can be used as a poor prognostic marker in non-Hodgkin’s lymphomas,
and the mutational change of gene may operate in the lymphomagenesis.
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and 19 NK/T cell lymphomas [NK/T]). Forty-two cases were
nodal and 108 cases were extranodal. The extranodal sites
were 44 gastrointestinal tracts, 17 nasal cavities, 15 Waldey-
er’s rings, 12 ocular adnexae, 3 salivary glands, 3 thyroid gla-
nds, 3 testes, and 11 others. The median age of patients was
53.8 yr (15-88 yr). Ninty-six patients were male and fifty-
four patients female. The patients were classified according
to the Ann Arbor clinical staging system; 49 stage I, 58 stage
II, 28 stage III, and 15 stage IV. The patients were classified
according to the International Prognostic Index (IPI); 105
low risk (0, 1), 33 intermediate risk (2, 3), and 12 high risk
(4, 5). Twenty-seven patients died from malignant lymphoma
between 1 month to 58 months (mean; 13.7 months). One
hundred twenty-three patients survived, and the mean fol-
low-up duration was 26.9 months (2-120). This investigation
was performed after obtaining an informed consent from all
the patients involved in our study.
Tissue microarray
All slides were reviewed, and the appropriate area was mar-
ked and selected for tissue microarray. Agar blocks for tissue
microarray were prepared as follows; Agar (4 g) was dissolved
into 100 mL distilled water and boiled in microwave for 2
min. It was solidified in the cast and routinely processed as
a tissue sample. The agar was embedded in paraffin. The se-
lected area of each case was holed by the punch biopsy tool
(2 mm in diameter) and transplanted into the agar block,
holed by the same biopsy tool. After all of the cases were re-
embedded into the agar block, the block was incubated at
Fig. 1. The nm23-H1 protein expression by LSAB method. (A) (-),
<5% positive cells; (B) (1+), 5-50% positive cells; (C) (2+), >50%
positive cells.
A B
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37℃for 30 min to mould the tissue in paraffin.
Immunohistochemical staining
The expression of nm23-H1 protein was immunohisto-
chemically stained on 4  m thick section from microarray
blocks by the use of LSAB method. Monoclonal antibody to
nm23-H1 (1:100, Novocastra Laboratories Ltd, U.K.) was
used as a primary antibody. Immunohistochemical staining
results for nm23-H1 protein were classified according to the
following criteria: (-), when less than 5% of tumor cells were
positive; (1+), when 5-50% of tumor cells were positive; (2+),
when more than 50% of the tumor cells were positive (Fig. 1).
PCR-SSCP analysis and DNA sequencing
Total 81 cases (58 DLBCL, 6 MZL, 4 TCLNOS, 13 NK/T)
were available for mutation study. DNA was extracted from
the formalin-fixed, paraffin-embedded tissue sections by the
use of the standard method with proteinase K digestion and
phenol/chloroform purification. The primers for PCR were
designed to amplify exons 1-5 as follows; Exon 1: (forward)
5′ gtctgaaaaacgtagcgccgg3′ , (reverse) 5′ cttaggtttgaactccggctg
3′ , Exon 2: (forward) 5′ gcttgagacggatgacgctgta3′ , (reverse)
5′ caggttaatcacagtgttctcc3′ , Exon 3: (forward) 5′ atgtccttaga-
tggtttgggggt3′ , (reverse) 5′ tttggtctcattcatggctgtat3′ , Exon
4: (forward) 5′ gccacattttctgctgtgatt3′ , (reverse) 5′ cccaaatcct-
tgtggcaact3′ , Exon 5; (forward) 5′ gtctaatgtccatggagcttc3′ ,
(reverse) 5′ cagatggtcggggatggtaac3′ . The total 20  L reac-
tion volume contained 3  L template, 1  L out of each oligo-
nucleotide primer, 2  L dNTP, 11  L ddH2O, 0.2  L Taq
polymerase, and 2  L 10× PCR buffer with Mg
2+. Cycling
conditions were as follows; an initial penetration at 95℃ for
5 min, 40 cycles each at 94℃for 1 min, at 56℃ for 30 sec,
at 72℃for 30 sec, followed by one cycle at 72℃for 10 min.
PCR products were visualized by electrophoresis in 1.8% (w/
v) agarose gel. Then the products were subjected to 8% non-
denaturation polyacrylamide gel electrophoresis and stained
with silver nitrate. DNA sequencing was performed in the
cases showing abnormal bands on PCR-SSCP by the use of
the Automatic Sequencer ABI 3730 (Applied Biosystem, Fos-
ter city, CA, U.S.A.).
Statistical analysis
Statistical significance was evaluated by using Kruskal-Wal-
lis test for independent groups. The survival curves were cal-
culated by using the Kaplan-Meier method, and then compa-
red with other prognostic variables by using a log-rank test.
All statistical analyses were two-sided with a significance level
of p≤0.05, and all analyses were performed by using the
SPSS statistical software (version 10.0, SPSS Inc., Chicago, IL,
U.S.A.).
RESULTS
The immunostaining for nm23-H1 protein in a reactive
lymph node showed a positive reaction in the cytoplasm of
centroblasts in germinal centers and transformed lymphocytes
in the interfollicular area. The staining in lymphoma cells
was also primarily cytoplasmic. Of the 150 non-Hodgkin’s
lymphomas, 58 (38.6%) cases were (2+) and 46 (30.7%) cases
(1+) for nm23-H1 protein (Table 1). According to the his-
tologic types, 45.9% of DLBCL, 16.7% of MZL, 66.7% of
DLBCL, Diffuse large B cell lymphoma; MZL, Marginal zone B cell lym-
phoma; MCL, Mantle cell lymphoma; TCLNOS, Peripheral T cell lym-
phoma, not otherwise specified; NK/T, NK/T cell lymphoma. -, less than
5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive;
2+, more than 50% of the tumor cells were positive. p=0.229.
- 1+ 2+ Total
nm23 staining
Type
DLBCL 20 (23.5%) 26 (30.6%) 39 (45.9%) 85 (100%)
MZL 13 (72.2%) 2 (11.1%) 3 (16.7%) 18 (100%)
MCL 0 (0%) 1 (33.3%) 2 (66.7%) 3 (100%)
TCLNOS 8 (32.0%) 10 (40.0%) 7 (28.0%) 25 (100%)
NK/T 5 (26.4%) 7 (36.8%) 7 (36.8%) 19 (100%)
Total 46 (30.7%) 46 (30.7%) 58 (38.6%) 150 (100%)
Table 1. The nm23-H1 protein expression according to the histo-
logic types
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were
positive; 2+, more than 50% of the tumor cells were positive.
- 1+ 2+ p value
nm23 staining
Age <60 30 (34.9%) 21 (24.4%) 35 (40.7%) 0.141
(yr) >60 16 (25.0%) 25 (39.1%) 23 (35.9%)
Sex Male 31 (32.3%) 32 (33.3%) 33 (34.4%) 0.349
Female 15 (27.8%) 14 (25.9%) 25 (4.3%)
Site Nodal 12 (28.6%) 17 (40.5%) 13 (30.9%) 0.247
Extranodal 34 (31.5%) 29 (26.8%) 45 (41.7%)
Table 2. The nm23-H1 protein expression according to age, sex
and the nodal or extranodal sites
*Value in bold type is statically significant. 
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were
positive; 2+, more than 50% of the tumor cells were positive. 
- 1+ 2+ p value
nm23 staining
Stage I, II 34 (31.8%) 30 (28.0%) 43 (40.2%) 0.547
III, IV 12 (27.9%) 16 (37.2%) 15 (34.9%)
IPI 0,1 39 (37.1%) 27 (25.8%) 39 (37.1%) 0.019
2,3 6 (18.2%) 14 (42.4%) 13 (39.4%)
4,5 1 (8.3%) 5 (41.7%) 6 (50.0%)
Table 3. The nm23-H1 protein expression according to the Ann
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MCL, 28.0% of TCLNOS, and 36.8% of NK/T lymphomas
were (2+). In MZL, there was a lower expression tendency of
nm23-H1 protein than in other types without statistical sig-
nificance. The age, sex, and the nodal or extranodal sites were
not correlated with nm23-H1 protein expression (Table 2).
The nm23-H1 protein expression was significantly correlat-
ed with IPI score (p=0.019) but not with the Ann Arbor clini-
cal stage (Table 3).
The survival rates in T cell lymphomas were worse than in
B cell lymphoma (p=0.0415, Table 4). The higher Ann Arbor
clinical stages (p=0.0000, Table 4), and IPI scores (p=0.0000,
Table 4) were significantly associated with poor outcomes. The
patients with (2+) expression of nm23-H1 protein showed
the lower survival rate than those with negative or (1+) ex-
pression (p=0.0039, Table 4, Fig. 2). The high expression of
nm23-H1 protein was associated with poor survival rates in
B and T cell lymphomas (p=0.0013, Fig. 3). Even in the same
Ann Arbor clinical stages (stage I, II and stage III, IV), and
IPI groups (low, intermediate, and high), the patients with
(2+) expression of nm23-H1 protein showed the lower survi-
val rate than those with negative or (1+) expression (p=0.0042
and p=0.0483, Fig. 4). 
By PCR-SSCP technique, the mutations were detected in
6 cases (10.3%) out of DLBCL and 4 cases (30.7%) out of
NK/T. No mutation was found in MZL and TCLNOS (Table
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Fig. 2. The survival curve according to nm23-H1 protein expression
(p=0.0039). -, less than 5% of tumor cells were positive; 1+, 5-50%
of tumor cells were positive; 2+, more than 50% of the tumor cells
were positive. 
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Fig. 3. The survival curve of nm23-H1 protein expression in B cell lymphoma (A) and T cell lymphoma (B) (p=0.0013).
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
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*Values in bold types are statistically significant. 
Stage, Ann Arbor stage; IPI, International Prognostic Index (IPI); -, less
than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were pos-
itive; 2+, more than 50% of the tumor cells were positive.
Factors Patient (n) Mean survival (mon) p value
Type B cell lymphoma 106 97 0.0415
T cell lymphoma 44 53
Stage I 49 117 0.0000
II 58 83
III 28 71
IV 15 26
IPI 0, 1 105 106 0.0000
2, 3 33 42
4, 5 12 9
Nm23-H1 - 46 89 0.0039
staining 1+ 46 109
2+ 58 66
Table 4. Univariate analysis of factors influencing overall survival
Type Number of total cases Number of mutation cases
DLBCL 58 6 (10.3%)
MZL 6 0 (0%)
TCLNOS 4 0 (0%)
NK/T 13 4 (30.7%)
Total 81 10 (12.3%)
Table 5. nm23-H1 mutation according to the histologic types
p=0.127.
A B5). These mutations were not correlated with age (p=0.071),
sex (p=0.813), nodal or extranodal sites (p=0.738), Ann Arbor
clinical stage (p=0.412), IPI (p=0.239), and survival rate (p=
0.1208). The mutation sites were as follows; five cases in
exon 1, two cases in exon 2, two cases in exon 1 and 2, and
one case in exon 4. Sequencing was performed in eight out
of ten cases. All of the four cases with exon 1 mutation showed
C G transversion at nucleotide 55 (gi 468541) (Fig. 5).
Three out of four cases with mutation in exon 2 showed inser-
tional mutation after the nucleotide at 2257 (gi 468541) and
the other one showed insertional mutation after the nucleotide
at 2084 (Fig. 5). There was a weak correlation between the
mutations and protein expression of nm23-H1 (p=0.057).
DISCUSSION
The human protein nm23-H1 is one of the human homo-
logues of Drosophila awd (15). Eight different genes of this
family have been identified in human, and their expressions
are linked to suppression of tumor metastasis, differentiation,
apoptosis, and proliferation (16, 17). nm23-H1 and -H2 are
nucleoside diphophate kinase, and metastasis suppression was
observed in several tumor cell lines transfected with nm23-
H1 gene (18, 19). However, the biochemical mechanisms
underlying the metastasis-suppressing action of nm23-H1
are largely unknown. The nm23 proteins are multifunction-
al, and they interact with many different proteins, some of
which are involved in cancer progression (20). Indeed, the
amount of nm23 increased in normal lymphocytes in response
to mitotic stimulation and paralleled the increase in DNA
synthesis (21). Our results also demonstrate the high expres-
sion of nm23-H1 protein is associated with poor prognosis.
Therefore, the nm23 protein has a different and possibly var-
ied role in tumors of different origins.
Niitsu et al. (11, 12) reported that serum levels of nm23-
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Fig. 5. nm23-H1 mutation by sequencing. (A) All of four cases with exon 1 mutation show the point mutation at the same site (*, C  G). (B)
Three of four cases with exon 2 mutation reveal the insertional mutation at the same site (*).
A B
GGCGCGTTTCGGGTGCTGGCGGCTGCAGCCGGAGTTCAAACCTSSGA
150                     160                     170                    180
TGCAGCCGGAGTTCA  C
ATTTTGATTCCTTCATAGTATAGGAGAACACTGTGATTAACCTGA
180                    190                  200                   210                   220
* *
ACACTGTGNATTAACC
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Fig. 4. The survival curve of nm23-H1 protein expression according to the same Ann Arbor clinical stage (A, Stage III and IV, p=0.0042) and
the same International Prognostic Index (B, IPI 2 and 3, p=0.0483).
-, less than 5% of tumor cells were positive; 1+, 5-50% of tumor cells were positive; 2+, more than 50% of the tumor cells were positive.
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A BH1 in aggressive non-Hodgkin’s lymphomas were signifi-
cantly higher than those in controls, and that high nm23-H1
levels were correlated with poor prognosis. Moreover, Niitsu
et al. (8, 9) reported 58.1% (100/172 patients) of DLBCL,
33.3% (5/15 patients) of MZL, 66.7% (12/18 patients) of
MCL, 25.5% (12/47 patients) of TCLNOS, and 42.9% (9/21
patients) of NK/T were strongly positive (more than 70%)
for nm23-H1. The survival rates were significantly lower in
the patients with nm23-H1-positive lymphomas than in those
with nm23-H1-negative lymphomas. 
In our study, the degree of nm23-H1 protein expression
was significantly correlated with IPI, but not with the age,
sex, nodal or extranodal sites, and histologic types. The strong
expression of nm23-H1 protein was significantly correlated
with poor survival rate. Even in the same Ann Arbor clinical
stage, IPI and histologic type (B and T cell lymphomas), the
high expression of nm23-H1 protein was significantly corre-
lated with poor survival rates. The results of this study were
similar to the previous reports of Niistu et al. (8, 9).
Mutational events of nm23 have not been frequently ob-
served in human cancers, and its role in malignancy is con-
troversial (22). Some data on colon and ovarian cancers sug-
gested that mutations of nm23-H1 gene were associated with
the presence of metastases, advanced disease, and poor sur-
vival (23, 24). In neuroblastoma, a particular point muta-
tion (Ser 120 Gly) affecting the protein folding was related
to the aggressiveness (25). However, other groups were unable
to detect any mutation of nm23-H1 gene in liver metastases
of colon cancer, breast cancer, and hepatocellular carcinoma
(3, 26-28). In malignant lymphomas, the mutational study
by Aryee et al. (13) did not show any mutations by PCR-
SSCP method.
In this study, we evaluated the nm23-H1 gene mutation
by PCR-SSCP method and sequencing. We detected nm23-
H1 mutation in non-Hodgkin’s lymphoma. Ten out of eigh-
ty-one cases showed nm23-H1 mutations by PCR-SSCP me-
thod. These mutations were not correlated with clinicopatho-
logic parameters. However, interestingly enough, the muta-
tion was only found in DLBCL and NK/T lymphomas, but
not in other types. In addition, the point mutation of exon 1
and insertional mutation of exon 2 were detected at the same
sites; C to G transversion at nucleotide 55 of exon 1, and inser-
tional mutation after the nucleotide at 2257. Bafico et al. (29)
reported that a common polymorphic sequence (C to T tran-
sition, 30 nucleotides upstream from the 5′ splice site of exon
1) in colorectal cancers, and Cipollini et al. (22) found that
nm23-H1 gene mutation (C to A transversion at nucleotide
-79 of exon 1) in breast cancers. The same sequence variants
as the present study have not been described so far.
Because nm23-H1 protein can be easily examined at the
time of conventional phenotypic examinations for the diag-
nosis of lymphoma, it may be used as a prognostic marker of
non-Hodgkin’s lymphoma in addition to known prognostic
indicators. We found the new mutation sites in nm23-H1
gene. The role of these mutations in non-Hodgkin’s lymphoma
needs further investigation.
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